Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis

Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis

Abstract Background Venous thromboembolism (VTE) affects nearly 1 million Americans annually, and many benefit from continued anticoagulation after the initial 3‐ to 6‐month treatment period (secondary prevention). Objectives To determine whether warfarin, apixaban, or rivaroxaban is associated with...

Full description

Bibliographic Details
Main Authors: Neil A. Zakai, Rob F. Walker, Richard F. MacLehose, Insu Koh, Alvaro Alonso, Pamela L. Lutsey
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
anticoagulants
factor Xa inhibitors
secondary prevention
venous thromboembolism
warfarin
Online Access:https://doi.org/10.1002/rth2.12575

Similar Items

Similar Items